Navigation Links
MEM in Medical Technology

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

-Triggers $5 Million Payment from Roche- MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cogni...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia

- Establishes Plan for Biomarker Study - MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarker...

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

-Company to Host Conference Call at 9:00 a.m. EDT- MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

...munity. The Company reported new clinical data for mem 1414, its lead PDE4 inhibitor, demonstrating the c... in humans. In addition, the Company has nominated mem 68626 as the lead development candidate from its 5...r, we are pleased to report that we have nominated mem 68626 as the lead compound in our 5-HT6 antagonist...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...ths, highlighted by our positive Phase 2a data for mem 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for mem 3454 with our partner Roche, and the completion of...4996/MEM 63908, and initiate a biomarker study for mem 3454 in schizophrenia." Financial Results For ...
MEM in Biological Technology

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in c...

Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses

... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania. http://www.doublehelixdevelopment.c...

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

...E10 inhibitor program and from SMRI related to the mem 1003 program which were recognized in 2007 but not...administrative costs and costs associated with the mem 1003 program. General and administrative expense...ory Pharmaceuticals presented preclinical data for mem 68626, its lead 5-HT6 antagonist, in a poster pres...

Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

...nd our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for mem 1414, and advancing our 5-HT6 antagonist program into the clinic." Financ... $3.4 million decrease in costs associated with the clinical development of mem 1003. General and administrative expenses for the quarter ended March 31,...

Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

...lpha-7 Receptor Agonist Collaboration with Roche. mem 3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem 3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem 63908 and report top-line results in the fourth qu...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

...will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem ) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may ...

Agendia BV Appoints Clinical and Scientific Advisory Board

...esearch programs and provide critical evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...

Bionovo Announces Proposed Public Offering of Common Stock

...al Markets Corp. and Canaccord Adams Inc. are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford & Co. (Amex: mem ) acting as a co-manager. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...

Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000

... LOPAC (Sigma)

Culture medium: mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids

Assay medium: mem (Sigma)

Agonist: Isoproterenol (Sigma) ...

The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

...EK293 cell line expressing EGF receptor HEK Culture medium: mem (Sigma M2279) containing: 10% (v/v) FBS Geneticin G418...

4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...

More>>

Other Tags
(Date:12/22/2014)... As part of a company-wide ... in San Diego and surrounding areas, Golden ... care team with ongoing online training courses. , ... provided by Caregiverlist®. Caregiverlist® is “the premiere ... most reliable eldercare options, highest quality ratings and ...
(Date:12/22/2014)... December 22, 2014 Fad diets ... The reason why most fad diets have hung around ... problem with fad diets is that, as the body becomes ... dieter uncertain of how to reset the metabolism to return ... Diet Doc developed their all-inclusive diet plans that ...
(Date:12/22/2014)... LENEXA, Kan. (PRWEB) December 22, 2014 ... it will add a subscription option to their ad ... for report writing services. Customers can sign up for ... report writing hours each month at a deeply discounted ... pricing tiers, and each has a progressively discounted rate. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 On December ... joined by Pastor Gordon Cashwell for an episode to ... asks Gordon, “Why is it so important to you ... Jesus?” Cashwell replies, “We all should respect who Jesus ... was founded on Christian beliefs. That means that on ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
Breaking Medicine News(10 mins):Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
Other Contents